Stockscreener 앱 받기
201.55
0.57%
-1.16
시장 영업 전:
201.41
-0.14
-0.07%
전일 마감가:
$202.71
열려 있는:
$201.92
하루 거래량:
4.75M
Relative Volume:
0.67
시가총액:
$356.49B
수익:
$62.82B
순이익/손실:
$3.60B
주가수익비율:
99.41
EPS:
2.0274
순현금흐름:
$19.98B
1주 성능:
-2.44%
1개월 성능:
-4.75%
6개월 성능:
-8.04%
1년 성능:
+8.61%
1일 변동 폭
$200.02
$202.40
1주일 범위
$200.02
$209.51
52주 변동 폭
$176.57
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
201.55 | 356.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
948.45 | 845.77B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
221.32 | 532.77B | 96.36B | 21.04B | 17.80B | 8.6488 |
AZN
Astrazeneca Plc
|
182.85 | 283.57B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.03 | 278.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Stock: Is Wall Street Bullish or Bearish? - Barchart.com
AbbVie Inc. stock (US00287Y1091): Post-Humira growth and raised 2026 guidance - AD HOC NEWS
What to Know About This Fund’s $3 Million Blackstone Mortgage Trust Sale Amid Office Stress - The Motley Fool
AbbVie Stock: The Post-Humira Transition Is Working and the Road to $311 - TIKR.com
CFO CAPITAL MANAGEMENT LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Total operating expenses of AbbVie, Inc. CDR (CAD Hedged) – TSX:ABBV - TradingView
AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting - Yahoo Finance
Is It Too Late To Consider AbbVie (ABBV) After Its Recent Share Price Pullback? - Yahoo Finance
AbbVie Inc. stock (US00287Y1091): Q1 2026 sales surge on immunology and aesthetics growth - AD HOC NEWS
Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
AbbVie (NYSE: ABBV) grows Q1 2026 sales while boosting R&D and deals - Stock Titan
AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner - Insider Monkey
AbbVie Stock Beats Q1 Estimates as Skyrizi Hits $4.5B in a Single Quarter - TIKR.com
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines. - Yahoo Finance
AbbVie Q1 earnings loom: Buy or sell the stock ahead of results? - MSN
Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)? - Yahoo Finance
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson? - The Motley Fool
Number of shareholders of AbbVie, Inc. CDR (CAD Hedged) – NEO:ABBV - TradingView
AbbVie Announces $1.4B Manufacturing Campus in Durham, NC | 2026News and Statistics - IndexBox
AbbVie to Present at Bank of America Securities Healthcare Conference on May 6, 2026 - geneonline.com
AbbVie to Present at the Bank of America Securities Healthcare Conference - marketscreener.com
ABBV Stock Price, Quote & Chart | ABBVIE INC (NYSE:ABBV) - ChartMill
5 Must-Read Analyst Questions From AbbVie’s Q1 Earnings Call - The Globe and Mail
Is trending stock AbbVie Inc. (ABBV) a buy now? - MSN
Glenwood Academy students, AbbVie scientists team up for science fair projects - The Lansing Journal
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases at 2026 Digestive Disease Week - Investing News Network
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance
AbbVie presents IBD data at digestive disease conference By Investing.com - Investing.com Canada
AbbVie presents IBD data at digestive disease conference - Investing.com
Steroid use fell to 7% in AbbVie Crohn's study after 52 weeks - Stock Titan
Leukemia Therapeutics Market to Reach US$ 31.37 Billion by 2033 - openPR.com
AVIP BlackRock Advantage Large Cap Value Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
Federated Hermes MDT Market Neutral ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
LVIP Dimensional U.S. Core Equity 2 Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
OMC Financial Services LTD's AbbVie Inc(ABBV) Holding History - GuruFocus
Capital Planning LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook - The Motley Fool
ABBV Maintained by Evercore ISI Group -- Price Target Raised to $236 - GuruFocus
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold? - TradingView
Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus - Supply Chain Dive
Evercore Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $236 - Moomoo
US FDA declines to approve AbbVie's wrinkle treatment due to manufacturing concerns - Reuters
Sarofim Equity Fund's AbbVie Inc(ABBV) Holding History - GuruFocus
5,538 Shares in AbbVie Inc. $ABBV Acquired by Legacy Edge Advisors LLC - MarketBeat
Kornitzer Capital Management Inc. KS Acquires 5,020 Shares of AbbVie Inc. $ABBV - MarketBeat
Heritage Wealth Management, Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
Wellment Financial's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV) Reports Q1 Revenue Growth Despite Earnings Miss - GuruFocus
AB Sustainable Thematic Balanced Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie, Inc. CDR (CAD Hedged) Trade Ideas — TSX:ABBV - TradingView
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.82%
자본화:
|
볼륨(24시간):